lapatinib has been researched along with bexarotene in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (bexarotene) | Trials (bexarotene) | Recent Studies (post-2010) (bexarotene) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 642 | 67 | 348 |
| Protein | Taxonomy | lapatinib (IC50) | bexarotene (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 5.9 | |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.632 | |
| Cytochrome P450 26B1 | Homo sapiens (human) | 5.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Biller, BM; Tritos, NA | 1 |
| Cecil, DL; Disis, ML; Gad, E; Herendeen, DR; Lai, VP; Lubet, RA; O'Meara, MM; Park, KH; Treuting, PM | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Du, G; Lv, T; Ren, S; Sun, L; Wang, J; Yu, H | 1 |
2 review(s) available for lapatinib and bexarotene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in medical therapies for Cushing's syndrome.
Topics: Animals; Bexarotene; Cushing Syndrome; Etomidate; Humans; Ketoconazole; Lapatinib; Metyrapone; Mifepristone; Mitotane; Quinazolines; Somatostatin; Tetrahydronaphthalenes | 2012 |
3 other study(ies) available for lapatinib and bexarotene
| Article | Year |
|---|---|
A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Insulin-Like Growth Factor Binding Protein 2; Lapatinib; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Neoplasm Invasiveness; Precancerous Conditions; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; T-Lymphocytes; Tetrahydronaphthalenes; Tumor Cells, Cultured; Vaccines, Subunit | 2013 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation.
Topics: Adrenocorticotropic Hormone; Animals; Bexarotene; Drug Combinations; Drug Repositioning; Humans; Lapatinib; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Protein Interaction Maps; Retinoid X Receptor alpha | 2020 |